Jun 5 |
Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?
|
May 29 |
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
|
May 28 |
Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
|
May 24 |
5 Small Drug Stocks to Buy From a Recovering Industry
|
May 20 |
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
|
May 14 |
Acrivon Therapeutics GAAP EPS of -$0.73 beats by $0.11
|
May 14 |
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
|
May 10 |
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
|
May 9 |
While institutions own 26% of Acrivon Therapeutics, Inc. (NASDAQ:ACRV), private equity firms are its largest shareholders with 50% ownership
|
Apr 24 |
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
|